ERBB2 and breast carcinoma: The overexpression of HER-2 (neu/erbB2) is correlated with a poor prognosis in patients with breast cancer or oral squamous cell carcinoma, presumably due to an increased metastatic ability and resistance to various cancer chemotherapies [58, 59].